MorphoSys AG — Regulatory Filings 2001

Jul 4, 2001

News Details

Ad-hoc | 4 July 2001 07:13

MorphoSys AG english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Bayer extends Collaboration with MorphoSys – Agreement extended for 4 additional Years Martinsried/Munich, Germany, July 4, 2001 – MorphoSys AG (Neuer Markt: MOR) announced today an extension of its ongoing collaboration with Bayer for an additional four years. Under the terms of the original agreement, MorphoSys collaboration with Bayer was scheduled to last for two years, with an option to extend the collaboration for an additional four years. Bayer exercised their option to extend the agreement, and will continue making license payments to MorphoSys as well as milestone payments and royalties on any resulting antibody products. MorphoSys will generate fully human therapeutic antibodies against up to ten targets provided by Bayer. The first milestone in the collaboration was achieved in February 2001 through MorphoSys generation of a high-affinity antibody against an undisclosed Bayer target. The collaboration agreement also specifies other areas in which the companies will work together using MorphoSys technologies, including genomics research and diagnostics. end of ad hoc announcement (c) DGAP 04.07.2001 ——————————————————————————– WKN: 663200; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 040713 Jul 01